Novo Nordisk's CEO Mike Doustdar said the Danish pharma company is open to a direct listing on the New York Stock Exchange, which would replace its current American depositary receipt (ADR) structure. However, the company is not actively pursuing this change now, keeping it as a future option. The move would allow US investors to buy shares directly on the NYSE rather than through ADRs. Shares dropped over 2% following the announcement, while Novo Nordisk also outlined plans to diversify and expand its drug pipeline by 2030.
Novo Nordisk shares are trading at USD 38.28 on Pluang as of Sep 24, 2026 01:03 WIB, down 2.84% in the last day. The stock's market cap stands at $175.28 billion, reflecting its significant size in the health sector. On Pluang, 89% of order activity is buying, indicating strong investor interest despite recent price declines.
Viking Therapeutics surged 26.5% after releasing positive topline results from its GLP-1/GIP agonist VK2735 maintenance dosing study in adults with obesity. The data suggest multiple effective maintenance dosing schedules, potentially improving patie...
Novo Nordisk held its investor day in London, outlining its strategy for growth after its key obesity drugs lose patent protection. Despite plans for multiple new blockbusters and expansion into heart and liver disease treatments, analysts were unimp...
Novo Nordisk CEO Mike Doustdar revealed the company is actively considering mergers and acquisitions to strengthen its position in the competitive weight-loss drug market. He emphasized the company's interest in acquiring or partnering with firms tha...
Biotech stocks and leveraged ETFs were the biggest losers in the market, with Cue Biopharma dropping 23.7% despite positive Phase 2 clinical results. Leveraged ETFs tied to AMD, Strategy, and Novo Nordisk also saw sharp declines due to their daily-re...
Novo Nordisk's shares fell over 7% after the company announced long-term targets that failed to reassure investors about competition in the weight-loss drug market. The Danish drugmaker plans to launch multiple blockbuster drugs by 2030 and aims for ...
